Literature DB >> 25989498

Clinicopathological Findings of Chronic Rejection in a Face Grafted Patient.

Palmina Petruzzo1, Jean Kanitakis, Sylvie Testelin, Jean-Baptiste Pialat, Fanny Buron, Lionel Badet, Olivier Thaunat, Bernard Devauchelle, Emmanuel Morelon.   

Abstract

BACKGROUND: Skin chronic rejection (CR) in vascularized composite allotransplantation has not been included in the Banff classification yet. We report a face-transplant patient who developed cutaneous clinicopathologic changes suggestive of CR.
METHODS: The recipient was a 27-year-old man with severe disfigurement of the lower face due to a pyrotechnic explosion. He received a facial allograft, including mandible, cheeks, lips, and chin, in November 2009. Immunosuppression included antithymocyte globulins and bone-marrow infusion then steroids, tacrolimus, and mycophenolate mofetil.
RESULTS: During the first posttransplant year the acute rejection episodes were characterized by reversible oedema and erythema of the graft. Subsequently, the patient developed primary asymptomatic Epstein-Barr virus (EBV) infection, followed by EBV+ B-cell lymphoma and hepatic EBV-associated posttransplant smooth muscle tumors; therefore, the immunosuppressive treatment was greatly reduced. Since the second posttransplant year, the allografted facial skin became progressively sclerotic and presented pigmented macules on a background of hypopigmentation and teleangiectasias, resulting in a poikilodermatous aspect. Skin biopsies showed epidermal atrophy, basal cell vacuolization, and diffuse dermal sclerosis in the absence of significant dermal cell infiltration. The dermal capillaries showed thickened walls and narrowed lumina, whereas the large vessels did not show significant alterations. Neither donor-specific antibodies nor vascular Cd4 deposits were detected.A dysfunction of the graft functions occurred. It was evidenced by a decrease in mouth opening and modification of some phonemes although lip closure was still possible allowing food intake.
CONCLUSIONS: This is the first report suggestive of CR in a face allotransplantation after immunosuppression minimization.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25989498     DOI: 10.1097/TP.0000000000000765

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  17 in total

1.  Chronic rejection of human face allografts.

Authors:  Nicco Krezdorn; Christine G Lian; Michael Wells; Luccie Wo; Sotirios Tasigiorgos; Shuyun Xu; Thiago J Borges; Rayven M Frierson; Ewelina Stanek; Leonardo V Riella; Bohdan Pomahac; George F Murphy
Journal:  Am J Transplant       Date:  2018-11-10       Impact factor: 8.086

Review 2.  Soft Tissue Management in Facial Trauma.

Authors:  Tara L Braun; Renata S Maricevich
Journal:  Semin Plast Surg       Date:  2017-05       Impact factor: 2.314

3.  Craniomaxillofacial trauma management in austere and war zone environments - A role for composite tissue allotransplantation?

Authors:  A M Ghanem; T-M Borg; P Sadigh; S Myers; D J Smith; S Holmes
Journal:  Ann Burns Fire Disasters       Date:  2019-12-31

Review 4.  Accommodation and related conditions in vascularized composite allografts.

Authors:  Jeffrey L Platt; Christina L Kaufman; Mayara Garcia de Mattos Barbosa; Marilia Cascalho
Journal:  Curr Opin Organ Transplant       Date:  2017-10       Impact factor: 2.640

5.  Codominant Role of Interferon-γ- and Interleukin-17-Producing T Cells During Rejection in Full Facial Transplant Recipients.

Authors:  T J Borges; J T O'Malley; L Wo; N Murakami; B Smith; J Azzi; S Tripathi; J D Lane; E M Bueno; R A Clark; S G Tullius; A Chandraker; C G Lian; G F Murphy; T B Strom; B Pomahac; N Najafian; L V Riella
Journal:  Am J Transplant       Date:  2016-04-07       Impact factor: 8.086

Review 6.  Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration.

Authors:  Maximilian Kueckelhaus; Sebastian Fischer; Midas Seyda; Ericka M Bueno; Mario A Aycart; Muayyad Alhefzi; Abdallah ElKhal; Bohdan Pomahac; Stefan G Tullius
Journal:  Transpl Int       Date:  2015-09-14       Impact factor: 3.782

Review 7.  Composite tissue allotransplantation: opportunities and challenges.

Authors:  Jasper Iske; Yeqi Nian; Ryoichi Maenosono; Max Maurer; Igor M Sauer; Stefan G Tullius
Journal:  Cell Mol Immunol       Date:  2019-03-06       Impact factor: 11.530

8.  Immunoregulatory and lipid presentation pathways are upregulated in human face transplant rejection.

Authors:  Thet Su Win; William J Crisler; Beatrice Dyring-Andersen; Rachel Lopdrup; Jessica E Teague; Qian Zhan; Victor Barrera; Shannan Ho Sui; Sotirios Tasigiorgos; Naoka Murakami; Anil Chandraker; Stefan G Tullius; Bohdan Pomahac; Leonardo V Riella; Rachael A Clark
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

9.  Augmentation of Recipient Adaptive Alloimmunity by Donor Passenger Lymphocytes within the Transplant.

Authors:  Ines G Harper; Jason M Ali; Simon J F Harper; Elizabeth Wlodek; Jawaher Alsughayyir; Margaret C Negus; M Saeed Qureshi; Reza Motalleb-Zadeh; Kourosh Saeb-Parsy; Eleanor M Bolton; J Andrew Bradley; Menna R Clatworthy; Thomas M Conlon; Gavin J Pettigrew
Journal:  Cell Rep       Date:  2016-04-28       Impact factor: 9.423

Review 10.  Immunomodulatory Role of Mesenchymal Stem Cell Therapy in Vascularized Composite Allotransplantation.

Authors:  Richard Heyes; Andrew Iarocci; Yourka Tchoukalova; David G Lott
Journal:  J Transplant       Date:  2016-10-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.